CGON Insider Files: 5,000 Shares Sold Under 10b5-1; Vested Options Reported
Rhea-AI Filing Summary
Leonard E. Post, a director of CG Oncology, Inc. (CGON), reported transactions dated 09/30/2025. The filing shows a purchase/acquisition of 5,000 common shares and a simultaneous sale/disposition of 5,000 common shares sold under a Rule 10b5-1 trading plan at a weighted average price of $40.09. The reporter holds a fully vested director stock option with an exercise price of $0.60 covering 5,000 shares and reports total beneficial ownership of 119,077 shares following the transactions. The sale was effected under a 10b5-1 plan adopted on 09/06/2024.
Positive
- Sale executed under a Rule 10b5-1 plan, reducing concerns about opportunistic timing
- Director retains significant beneficial ownership of 119,077 shares after transactions
- Director stock option is fully vested, indicating alignment with the company
Negative
- Disposition of 5,000 shares (sale) at a weighted average price of $40.09
- Potential dilution from a vested option exercisable for 5,000 shares at $0.60
Insights
TL;DR Insider executed a planed sale while retaining meaningful holdings and holding vested low-strike options.
The reported activity is routine for directors managing equity positions. The 5,000-share sale at a weighted average of $40.09 was conducted under a pre-established Rule 10b5-1 plan, which reduces concerns about opportunistic timing. Simultaneously, the filing records an acquisition and a fully vested option with a $0.60 exercise price covering 5,000 shares, indicating potential future dilution if exercised but also alignment with long-term ownership. Beneficial ownership remains at 119,077 shares, which is material for governance but likely immaterial to CGON's market capitalization absent additional context.
TL;DR Transactions followed standard insider-disclosure practices and used a 10b5-1 plan, consistent with good governance if compliant.
The filing shows timely disclosure and notes the use of a 10b5-1 trading plan adopted 09/06/2024, which is an established mechanism for planned insider sales. The presence of a fully vested option with a very low strike price suggests historical compensation alignment but also potential for future share issuance if exercised. No amendments or corrective disclosures are present. From a governance perspective, the form contains the expected detail and explanations for the sale pricing range.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Director Stock Option (right to buy) | 5,000 | $0.00 | -- |
| Exercise | Common Stock | 5,000 | $0.60 | $3K |
| Sale | Common Stock | 5,000 | $40.09 | $200K |
Footnotes (1)
- The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Fully vested
